Cathy Kelly
Senior Writer
Cathy has covered US regulation and reimbursement policy for the biopharma industry since 2004, starting with the establishment of the Medicare Part D program. Since then, she has written extensively about developments in all major sectors of the US insurance market (Medicare, Medicaid and commercial plans). She has covered key legislation affecting biopharma, including the Medicare Prescription Drug, Improvement, and Modernization Act which created Part D, health care reform under President Obama, and the Inflation Reduction Act which establishes a government price negotiation program in Medicare for the first time and redesigns of the Part D benefit.
She has closely followed the increasing influence of pharmacy benefit managers and their use of formulary negotiations and rebates to control pricing. Cathy also has covered developments in health technology assessments, including the growing influence of the Institute for Clinical and Economic Review, and has monitored industry progress on novel drug contracting that reflects value-based pricing.
She has worked as a health care reporter and editor while raising three daughters. Cathy lives outside DC in Bethesda, MD, with her husband Sean.
Latest From Cathy Kelly
US Patent Office Plan To Expand Settlement Disclosure Requirements Welcomed By FTC
US Federal Trade Commission says the policy would enhance its ability to detect reverse payment settlements between pharmaceutical companies that raise antitrust concerns.
US House Bill Would Cover Obesity Drugs For Only Sliver Of New Medicare Enrollees
The significantly scaled back version of the Treat and Reduce Obesity Act is expected to cost the Part D program $1.7bn over 10 years.
US Patent Office Plan To Expand Settlement Disclosure Requirements Welcomed By FTC
US Federal Trade Commission says the policy would enhance its ability to detect reverse payment settlements between pharmaceutical companies that raise antitrust concerns.
340B Drug Diversion: Sanofi Suit Seeks Evidence In Pharmacy Contracts With Hospitals
Drug maker pursuing novel approach to establishing that contract pharmacies are improperly taking ‘title’ to 340B-discounted drugs, leading to diversion, which is prohibited by law.
Medicare Negotiation: Therapeutic Alternatives Selection Will Become More Predictable, CMS Says
The selection process timeline will not change, but as the Medicare price negotiation matures, industry will better understand how therapeutic alternatives are chosen to inform the process, according to an official with the Centers for Medicare and Medicaid Services.
Bipartisan House Support Remains Elusive In 340B Reform Effort
Republicans continue to take the lead on advancing reforms, while Democrats warn proposals could endanger a government program supporting safety-net care.